Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC)
- 7 April 2008
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 62 (1), 55-61
- https://doi.org/10.1016/j.lungcan.2008.02.015
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Predictive and prognostic value of FDG‐PET in nonsmall‐cell lung cancerCancer, 2007
- RETRACTED: 100 years of lung cancerRespiratory Medicine, 2006
- 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Advances in Chemotherapy of Non-small Cell Lung CancerChest, 2006
- Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Monitoring chemotherapy and radiotherapy of solid tumorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose UseJournal of Clinical Oncology, 2003
- Staging of Non–Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed TomographyNew England Journal of Medicine, 2003
- Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Prognostic Value of Thoracic FDG PET Imaging After Treatment for Non-Small Cell Lung CancerAmerican Journal of Roentgenology, 2000